Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders

Urea Cycle Disorders Consortium

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Sodium phenylbutyrate (NaPBA) is a commonly used medication for the treatment of patients with urea cycle disorders (UCDs). Previous reports involving small numbers of patients with UCDs have shown that NaPBA treatment can result in lower plasma levels of the branched-chain amino acids (BCAA) but this has not been studied systematically. From a large cohort of patients (n. =. 553) with UCDs enrolled in the Longitudinal Study of Urea Cycle Disorders, a collaborative multicenter study of the Urea Cycle Disorders Consortium, we evaluated whether treatment with NaPBA leads to a decrease in plasma BCAA levels. Our analysis shows that NaPBA use independently affects the plasma BCAA levels even after accounting for multiple confounding covariates. Moreover, NaPBA use increases the risk for BCAA deficiency. This effect of NaPBA seems specific to plasma BCAA levels, as levels of other essential amino acids are not altered by its use. Our study, in an unselected population of UCD subjects, is the largest to analyze the effects of NaPBA on BCAA metabolism and potentially has significant clinical implications. Our results indicate that plasma BCAA levels should to be monitored in patients treated with NaPBA since patients taking the medication are at increased risk for BCAA deficiency. On a broader scale, these findings could open avenues to explore NaPBA as a therapy in maple syrup urine disease and other common complex disorders with dysregulation of BCAA metabolism.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalMolecular Genetics and Metabolism
Volume113
Issue number1
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Inborn Urea Cycle Disorder
Branched Chain Amino Acids
Urea
Plasmas
Metabolism
Maple Syrup Urine Disease
4-phenylbutyric acid
Essential Amino Acids
Therapeutics
Multicenter Studies
Longitudinal Studies

Keywords

  • Branched-chain amino acids
  • Sodium phenylbutyrate
  • Urea cycle disorder

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. / Urea Cycle Disorders Consortium.

In: Molecular Genetics and Metabolism, Vol. 113, No. 1, 01.09.2014, p. 131-135.

Research output: Contribution to journalArticle

@article{2744fbaa650e483e8377119e66768707,
title = "Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders",
abstract = "Sodium phenylbutyrate (NaPBA) is a commonly used medication for the treatment of patients with urea cycle disorders (UCDs). Previous reports involving small numbers of patients with UCDs have shown that NaPBA treatment can result in lower plasma levels of the branched-chain amino acids (BCAA) but this has not been studied systematically. From a large cohort of patients (n. =. 553) with UCDs enrolled in the Longitudinal Study of Urea Cycle Disorders, a collaborative multicenter study of the Urea Cycle Disorders Consortium, we evaluated whether treatment with NaPBA leads to a decrease in plasma BCAA levels. Our analysis shows that NaPBA use independently affects the plasma BCAA levels even after accounting for multiple confounding covariates. Moreover, NaPBA use increases the risk for BCAA deficiency. This effect of NaPBA seems specific to plasma BCAA levels, as levels of other essential amino acids are not altered by its use. Our study, in an unselected population of UCD subjects, is the largest to analyze the effects of NaPBA on BCAA metabolism and potentially has significant clinical implications. Our results indicate that plasma BCAA levels should to be monitored in patients treated with NaPBA since patients taking the medication are at increased risk for BCAA deficiency. On a broader scale, these findings could open avenues to explore NaPBA as a therapy in maple syrup urine disease and other common complex disorders with dysregulation of BCAA metabolism.",
keywords = "Branched-chain amino acids, Sodium phenylbutyrate, Urea cycle disorder",
author = "{Urea Cycle Disorders Consortium} and Burrage, {Lindsay C.} and Mahim Jain and Laura Gandolfo and Lee, {Brendan H.} and Batshaw, {Mark L.} and Mendel Tuchman and Summar, {Marshall L.} and Baumgartner, {Matthias R.} and Berry, {Susan A.} and Stephen Cederbaum and Diaz, {George A.} and Annette Feigenbaum and Gallagher, {Renata C.} and Cary Harding and Georg Hoffmann and Kerr, {Douglas S.} and Brendan Lee and Uta Lichter-Konecki and McCandless, {Shawn E.} and Merritt, {J. Lawrence} and Andreas Schulze and Seashore, {Margretta R.} and Tamar Stricker and Susan Waisbren and Derek Wong and Mark Yudkoff and Nagamani, {Sandesh C S}",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.ymgme.2014.06.005",
language = "English (US)",
volume = "113",
pages = "131--135",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders

AU - Urea Cycle Disorders Consortium

AU - Burrage, Lindsay C.

AU - Jain, Mahim

AU - Gandolfo, Laura

AU - Lee, Brendan H.

AU - Batshaw, Mark L.

AU - Tuchman, Mendel

AU - Summar, Marshall L.

AU - Baumgartner, Matthias R.

AU - Berry, Susan A.

AU - Cederbaum, Stephen

AU - Diaz, George A.

AU - Feigenbaum, Annette

AU - Gallagher, Renata C.

AU - Harding, Cary

AU - Hoffmann, Georg

AU - Kerr, Douglas S.

AU - Lee, Brendan

AU - Lichter-Konecki, Uta

AU - McCandless, Shawn E.

AU - Merritt, J. Lawrence

AU - Schulze, Andreas

AU - Seashore, Margretta R.

AU - Stricker, Tamar

AU - Waisbren, Susan

AU - Wong, Derek

AU - Yudkoff, Mark

AU - Nagamani, Sandesh C S

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Sodium phenylbutyrate (NaPBA) is a commonly used medication for the treatment of patients with urea cycle disorders (UCDs). Previous reports involving small numbers of patients with UCDs have shown that NaPBA treatment can result in lower plasma levels of the branched-chain amino acids (BCAA) but this has not been studied systematically. From a large cohort of patients (n. =. 553) with UCDs enrolled in the Longitudinal Study of Urea Cycle Disorders, a collaborative multicenter study of the Urea Cycle Disorders Consortium, we evaluated whether treatment with NaPBA leads to a decrease in plasma BCAA levels. Our analysis shows that NaPBA use independently affects the plasma BCAA levels even after accounting for multiple confounding covariates. Moreover, NaPBA use increases the risk for BCAA deficiency. This effect of NaPBA seems specific to plasma BCAA levels, as levels of other essential amino acids are not altered by its use. Our study, in an unselected population of UCD subjects, is the largest to analyze the effects of NaPBA on BCAA metabolism and potentially has significant clinical implications. Our results indicate that plasma BCAA levels should to be monitored in patients treated with NaPBA since patients taking the medication are at increased risk for BCAA deficiency. On a broader scale, these findings could open avenues to explore NaPBA as a therapy in maple syrup urine disease and other common complex disorders with dysregulation of BCAA metabolism.

AB - Sodium phenylbutyrate (NaPBA) is a commonly used medication for the treatment of patients with urea cycle disorders (UCDs). Previous reports involving small numbers of patients with UCDs have shown that NaPBA treatment can result in lower plasma levels of the branched-chain amino acids (BCAA) but this has not been studied systematically. From a large cohort of patients (n. =. 553) with UCDs enrolled in the Longitudinal Study of Urea Cycle Disorders, a collaborative multicenter study of the Urea Cycle Disorders Consortium, we evaluated whether treatment with NaPBA leads to a decrease in plasma BCAA levels. Our analysis shows that NaPBA use independently affects the plasma BCAA levels even after accounting for multiple confounding covariates. Moreover, NaPBA use increases the risk for BCAA deficiency. This effect of NaPBA seems specific to plasma BCAA levels, as levels of other essential amino acids are not altered by its use. Our study, in an unselected population of UCD subjects, is the largest to analyze the effects of NaPBA on BCAA metabolism and potentially has significant clinical implications. Our results indicate that plasma BCAA levels should to be monitored in patients treated with NaPBA since patients taking the medication are at increased risk for BCAA deficiency. On a broader scale, these findings could open avenues to explore NaPBA as a therapy in maple syrup urine disease and other common complex disorders with dysregulation of BCAA metabolism.

KW - Branched-chain amino acids

KW - Sodium phenylbutyrate

KW - Urea cycle disorder

UR - http://www.scopus.com/inward/record.url?scp=84908550679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908550679&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2014.06.005

DO - 10.1016/j.ymgme.2014.06.005

M3 - Article

C2 - 25042691

AN - SCOPUS:84908550679

VL - 113

SP - 131

EP - 135

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -